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Inventions (DD882) Scientific Progress
This report describes the achievements of a multidisciplinary team from Draper Laboratory, MIT, the University of CaliforniaSanta Barbara, and the University of Massachusetts Medical School, on the DARPA/DSO project entitled "Engineered Nanoparticle for Virus Elimination by Opsonization (ENVELOP)", part of the 7-Day Biodefense program. On this program the team has developed a technology platform to produce broad spectrum anti-viral particles that block infection by respiratory viruses. We have produced two different types of anti-viral particles, one designed to counter human-adapted influenza A viruses and another to counter respiratory syncytial (RSV) and related viruses. These were each demonstrated to block viral infection in cell culture and/or in animal models. Our team has been working to develop and demonstrate an aerosolized form that can be delivered to the human respiratory tract to prevent the spread of virus during an outbreak or to treat infected individuals. The anti-viral particles are comprised of liposomes with surface-attached glycan receptors that bind virus. The receptors are designed so that they mimic the natural viral receptors in the human airway and adhere to the virus with high affinity. A significant advance was development of a process to identify and synthesize these biomimetic viral receptors. This process, validated with human-adapted influenza A and RSV, can be applied to any group of viruses. Glycan identification was accomplished by combining information about glycans present on target cells, in this case airway epithelial cells, structural analysis of viral binding proteins, and high-throughput glycan array screening of viral specificity. LSTc for human-adapted influenza A and HSocta, a heparin derived octasaccharide, for RSV were selected on the basis of their binding affinity for the virus and for their ease of production/purification. Purified glycans were covalently linked to lipids via one of two glycolipid synthesis processes developed and optimized on the program. Glycan-bearing lipids were formulated into liposomes with DOPC and cholesterol, other lipids that have been used in previously FDA-approved liposomal products. Glycan purification, glycolipid synthesis, and liposome production processes were each tailored so that they are scalable and able to be utilized under GLP or GMP. LSTc-labeled liposomes inhibited the ability of influenza A to infect cells in vitro with broad influenza specificity, blocking all H1N1 and H3N2 strains tested. A single dose of LSTc-labeled liposomes significantly extended the lifetime of mice infected with the lethal dose of mouse-adapted influenza H1N1, and increased the rate of post-infection survival relative to infected mice that received no liposomes or liposomes lacking LSTc. This indicated that the LSTc on the liposome surface was able to bind to influenza virus in mice and prevent the virus from productively entering airway cells, and demonstrated that the liposome molecule was able to effectively interfere with influenza infection in vivo. Several studies confirmed that the mechanism of action of LSTc-bearing liposomes to be consistent with binding to viral particles and preventing their entry into host cells. Pharmacokinetic studies in mice using radiolabeled LSTc-bearing liposome indicate that liposome reside in the lungs for ~2 days, making prophylaxis possible. We also demonstrated the platform in developing liposomes bearing receptors for respiratory syncytial virus (RSV). RSV is known to bind heparan sulfate, and we have identified and isolated specific heparan-sulfate derived glycans, conjugated them to DOPE to produce a glycolipid, and produced glycan-bearing liposomes that inhibited RSV infection in vitro. This indicates that the glycan-bearing liposome platform has the potential for broad-reaching anti-viral activity. 
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EXECUTIVE SUMMARY
This report describes the achievements of a multidisciplinary team from Draper Laboratory, MIT, the University of California -Santa Barbara, and the University of Massachusetts Medical School, on the DARPA/DSO project entitled "Engineered Nanoparticle for Virus Elimination by Opsonization (ENVELOP)", part of the 7-Day Biodefense program. On this program the team has developed a technology platform to produce broad spectrum anti-viral particles that block infection by respiratory viruses. We have produced two different types of anti-viral particles, one designed to counter human-adapted influenza A viruses and another to counter respiratory syncytial virus (RSV) and related viruses. These were each demonstrated to block viral infection in cell culture and/or in animal models. Our team has been working to develop and demonstrate an aerosolized form that can be delivered to the human respiratory tract to prevent the spread of virus during an outbreak or to treat infected individuals.
The anti-viral particles are comprised of liposomes with surface-attached glycan receptors that bind virus. The receptors are designed so that they mimic the natural viral receptors in the human airway and thus adhere to the virus with high affinity. A significant advance was development of a process to identify and synthesize these biomimetic viral receptors. This process, validated with human-adapted influenza A and RSV, can be applied to any group of viruses. Glycan identification was accomplished by combining information about glycans present on target cells, in this case airway epithelial cells, structural analysis of viral binding proteins, and high-throughput glycan array screening of viral specificity. LSTc for human-adapted influenza A and HSocta, a heparin-derived octasaccharide, for RSV were selected on the basis of their binding affinity for the virus and for their ease of production/purification. Purified glycans were covalently linked to lipids via one of two glycolipid synthesis processes developed and optimized on the program. Glycan-bearing lipids were formulated into liposomes with other lipids that have been used in previously FDA-approved liposomal products. Glycan purification, glycolipid synthesis, and liposome production processes were each tailored so that they are scalable and able to be utilized under GLP or GMP.
LSTc-labeled liposomes inhibited the ability of influenza A to infect cells in vitro with broad influenza specificity, blocking all H1N1 and H3N2 strains tested. A single dose of LSTc-labeled liposomes significantly extended the lifetime of mice infected with the lethal dose of mouse-adapted influenza H1N1, and increased the rate of post-infection survival relative to infected mice that received no liposomes or liposomes lacking LSTc. This indicated that the LSTc on the liposome surface was able to bind to influenza virus in mice and prevent the virus from productively entering airway cells, and demonstrated that the liposome molecule was able to effectively interfere with influenza infection in vivo. Several studies confirmed that the mechanism of action of LSTc-bearing liposomes to be consistent with binding to viral particles and preventing their entry into host cells. Pharmacokinetic studies in mice using radiolabeled LSTc-bearing liposome indicate that liposome reside in the lungs for 2 to 3 days, making prophylaxis possible.
We also demonstrated the platform in developing liposomes bearing receptors for respiratory syncytial virus (RSV). RSV is known to bind heparan sulfate, and we have identified and isolated specific heparan-sulfate derived glycans, conjugated them to DOPE to produce a glycolipid, and produced glycan-bearing liposomes that inhibited RSV infection in vitro. This demonstrated that the glycan-bearing liposome platform has the potential for broad-reaching anti-viral activity that can inhibit the spread of respiratory virus. Figure 1 Tracheal and alveolar tissue staining………………………………………………………………………………..……....6 Figure 2 Glycan receptor preferences of HA from avian-adapted and human-adapted influenza…………….7 Figure 3 Interaction of cone and umbrella glycan configurations with the receptor binding pocket…….….7 Figure 4 Mixed 2→3 (3') and 2→6 (6') glycan binding of PR/8……………………………………………………………….……..8 Figure 5 LSTa and LSTc glycan moieties………………………………………………………………………………..………….………9 Figure 6 Specificity of LSTc for human-adapted HA and LSTa for avian-adapted HA……………..………….……..9 Figure 7 Heparan sulfate octasaccharide identified as an effective RSV binding glycan………..………….……10 Figure 8 Purification scheme for the octasaccharide……………………………………………………………………………..10 Figure 9 Efficacy of heparin sodium and heparin sulfate octasaccharide……………………………………….………11 Figure 10 Reductive amination for conjugating glycan to an amine-functionalized lipid backbone………….12 Figure 11 Amino-oxy synthesis scheme for linkage of HS-octasaccharide to DOPE……………………………..…..13 Figure 12 Lipids used in formulation of liposomes……………………………………………………………………………..…...14 Figure 13 Scanning electron micrograph of LSTc-bearing liposomes………………………………………………….…...15 Figure 14 Glycan array analysis of the effect of glycan-bearing liposomes…………………………………………….…17 Figure 15 Comparison of in vitro activity of LSTc-bearing liposome batches…………………………………..……….18 Figure 16 Comparison of LSTc-labeled liposomes vs. PR/8 (H1N1) and Philippines X-79 (H3N2)………………19 Figure 17 LSTc-bearing liposomes are able to block the cytopathic effect of influenza A…………………….…..20 Figure 18 Efficacy of LSTc-bearing liposomes in inhibiting PR/8 infection of NHBE cells………………..….…….21 Figure 19 LSTc-liposomes extend survival following a lethal influenza A challenge……………………………....…22 Figure 20 LSTc-liposomes pre-mixed with Philippines X-79 do not block infection in mice…………..……..…..22 Figure 21 Pharmacokinetic profiles of liposomes lacking LSTc in the lungs of mice………………………………….23 Figure 22 Pharmacokinetic profile of LSTc-labeled liposomes in the lungs of mice……………………………..…..24 Figure 23 In vitro efficacy of combinations of LSTc-and LSTa-labeled liposomes against PR/8………….……25 Figure 24 Transmission electron microscopy of liposome-virus interactions……………………………………..…….25 Figure 25 In vitro efficacy of LSTc-bearing liposomes added at various times relative to infection…..……..26 Figure 26 Prophylactic in vitro efficacy of LSTc-bearing liposomes…………………………………………………………..27 Figure 27 Method used to measure binding affinity of LSTc-labeled liposomes to influenza HA……………..27 Figure 28 LSTc-containing liposomes inhibit binding of influenza A virus to A549 cells…………………………...28 Figure 29 Effect of zanamivir on LSTc-labeled liposome inhibition of PR/8 infection of MDCK cells…….…..29 Figure 30 Prevention of mortality associated by LSTc-bearing liposomes with or without zanamivir……...30 Figure 31 Efficacy of zanamivir-loaded liposomes……………………………………………………………………………………31 Table 1 Distribution of deposition of aerosolized liposomes…………………………………………………………..….16 Table 2 HAI activity of leading liposome candidates vs different viral strains……………………………….…….17 Table 3 Inhibition of cell toxicity caused by H1N1 and H3N2 influenza strains……………………………………20 To elaborate the diversity of the 2→6 glycans predominantly expressed in the upper respiratory tissues, we co-stained representative human tracheal sections with a panel of well-defined lectins. Sambucus nigra agglutinin (SNA-I) is a prototypic lectin that specifically binds to 2→6 glycans, while Jacalin and Concanavalin A (Con A) respectively bind to specific motifs in O-linked and N-linked (trimannosyl core) glycans. Preliminary lectin staining studies demonstrate a widespread distribution of N-linked 2→6 (on ciliated cells) in contrast to the localized distribution of O-linked 2→6 (on goblet cells) glycans on the apical side of the tracheal section (Figure 1 ). In addition, staining of human tracheal tissue 7-Day Biodefense: ENVELOP 6 sections with another lectin, LEL, showed extensive staining on the apical surface of the tracheal tissue points to the distribution of N-and O-linked glycans comprising of long oligosaccharide branches with lactosamine repeats. These glycans are predominantly in the upper respiratory tract while alveolar cells of the deep lung were dominated by glycans bearing 2→3-linked sialic acid. Further 'micro' level characterization was performed by MALDI-MS profiling of N-linked sialylated glycans isolated from a representative human bronchial epithelial (HBE) primary cell line. The MALDI-MS analysis corroborated the lectin staining and showed substantial glycan diversity on human tracheal and bronchial cells as well as the predominant expression of 2→6 glycans. MS/MS analysis of mass peaks further demonstrated the presence of long oligosaccharide branches with multiple lactosamine repeats. The conclusion from these analyses is that human tracheal and bronchial tissue displays higher molecular weight glycans that are long rather than branched, with a predominance of long 2→6-linkages to sialic acid.
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Top-down approach: Common structure and topology of glycans targeted by influenza A
The HAs from avian-adapted and human-adapted influenza A strains have been demonstrated to have a binding preference for 2→3 and 2→6-linked sialic acid, respectively, though there are notable exceptions. Using screening of glycan arrays with HAs from various influenza A strains, our team performed a more detailed topological analysis of influenza glycan receptors (Figure 2 ). This revealed common glycan structures preferred by avian-and human-adapted influenza strains, either in the closed (cone-like) or open (umbrellalike) conformations among the 2→3 and 2→6-linked glycans (Figure 3 ). Binding to either of these configurations can distinguish between avian-adapted and human-adapted influenza strains with 100% accuracy. Long 2→6 sialylated glycans with an umbrella-type topology are those favored by human-adapted strains. These were the same types of glycans found prominent on tracheal and bronchial epithelial cells using bottom-up analysis. Influenza strains adapted for mouse infection, the animal model used on this project, demonstrate binding to a variety of 2→3 and 2→6 sialylated glycans in both the cone and umbrella conformations. This is demonstrated for the influenza A H1N1 strain PR/8 in a dose-dependent direct binding assay with five defined 2→3 and 2→6 glycans that differ in their surface linkage and length characteristics and represent both cone-like and umbrella-like topologies. In this study, PR/8 showed the ability to bind both α2→3 and α2→6 linked sialylated glycans with reasonable affinity (Figure 4 ). Based on this data and our need to demonstrate efficacy in a mouse model, our initial approach was to construct one liposome displaying an umbrella-like topology 2→6 sialylated glycan and another displaying a cone-like 2→3 sialylated glycans. These were to be combined to generate a mixture capable of binding and inhibiting PR/8 and other mouse-adapted strains, in addition to a wide range of avian-adapted and humanadapted subtypes. Structural and binding preferences of these strains were integrated and used to identify one cone-like 2→3 sialylated glycan motif and one umbrella-like 2→6 sialylated glycan motif that were bound with high affinity. Glycan selection was also based on demonstrated high-affinity binding to human-or avian-adapted HA subtypes in glycan arrays, and for ease of synthesis and purification. LSTc (Neu5Ac2→6Gal1→4GlcNAc1→3Gal1→4Glc, 2→6 sialylated, umbrella-like configuration) fits these criteria for binding human-adapted strains, while LSTa (Neu5Ac2→3Gal1→4GlcNAc1→3Gal1→4Glc, 2→3 sialylated, cone-like configuration) fits the criteria for high affinity binding to avian-adapted strains ( Figure 5 ). LSTa and c are present in milk and can be specifically isolated and purified from this plentiful source or chemoenzymatically synthesized. For our studies, free oligosaccharides of LST a/c were separated by gel filtration and high performance liquid chromatography (HPLC) using a normal phase column separation. We successfully obtained ~100 mg of each, and structures were confirmed by proton NMR analysis that matched a reference spectrum for LSTc, specifically the identity of the four distinct monosaccharides and the presence of 2→6 sialic acid at stoichimetric levels. 
Glycan receptor design and purification: RSV
To demonstrate the glycan-labeled liposome platform was useful in generating anti-viral particles for respiratory viruses other than influenza, we identified and purified a glycan receptor able to interfere with infection by respiratory syncytial virus (RSV), a major cause of respiratory illness in the newborn infants, young children, the elderly, and severely immunocompromised patients. Our approach to glycan identification was more direct than that used for influenza A. Previous studies definitively demonstrated that cell surface heparan sulfate, a complex highly charged polysaccharide, plays an important role in RSV infection. The RSV 7-Day Biodefense: ENVELOP 10 virion directly interacts with cell surface heparan sulfate via its F and G envelope glycoproteins. Importantly, attachment and infectivity of RSV strains was diminished in the presence of soluble heparan sulfate, and removal of cell surface heparan sulfate substantially limited infectivity (Krusat and Streckert, 1997; Feldman et al., 2000) . As such, construction of a liposome bearing an oligosaccharide derived from heparan sulfate in a multivalent display was expected to bind to and block RSV infection.
Detailed structural analysis of the F and G proteins identified a putative heparan sulfate binding site. Figure 7 .
This particular octasaccharide was chosen for a number of reasons: it has a relatively high charge density (three sulfates per disaccharide) to enable a high affinity interaction with the RSV virion, the presence of three iduronates within the octasaccharide allowed for a high degree of conformational flexibility, permitting sampling of the best topologies for high affinity binding, and a simple procedure to isolate the octsaccaharide from bulk heparin material in sufficient amounts for structure/function studies was developed. The purification route, which is amenable to scale-up, is shown in Figure 8 . 
Step #1: Digestion of Heparin with Heparinase
Step #2: Preparative Size Exclusion Chromatography to Isolate Octa
Step #3: Polishing with Strong Anion Exchange Optimal heparinase concentration and reaction conditions for digestion of heparin were chosen to yield significant amounts of octasaccharides (from ~30-50 mer). Since heparinase is a lyase, it cleaves the glycosidic linkage only at selected places (yielding even-numbered saccharide chains) and leaves behind a 4,5 double bond, a chemical signature that can readily be monitored at 232 nm. Using 232 nm monitoring, we then separated the oligosaccharide chains produced by size exclusion chromatography, and, after isolating the octasaccharide pool, polished the material using strong anion exchange. After desalting, multimilligram amounts of purified octasaccharide were obtained.
The purified heparan sulfate octasaccharide (HSocta) had strong anti-RSV properties when tested for its ability to block infection of MDCK cells (Figure 9) . Full-length heparin sodium (the starting material) or purified HSocta was added to Vero cells simultaneously with RSV. Each material showed a significant ability to block RSV infection, with heparin sodium inhibiting >90% of PFU formation at a concentration of 1 µg/ml indicating that the native heparin displays surface glycans that very effectively bind RSV. The purified octasaccharide had less activity, blocking PFU formation roughly 50% at 1 µg/ml or higher. This was expected and is due to the inability of the purified material to form multivalent interactions with the RSV virion. Displaying HSocta on the surface of a liposome should recapitulate the multivalent binding while eliminating the anticoagulant and other detrimental effects of native heparin. 
Glycan chemistry design and incorporation strategy
Our approach to functionalizing the liposome surface has been to conjugate the viral glycan receptors to a linker then to a lipid anchor to create a glycolipid that could be incorporated into liposomes. Alternatives were to conjugate the carbohydrate to a different membrane-compatible molecule such as a protein in order to anchor it to the liposome surface, or to modify the surface of the liposome with the glycan after extrusion. The approach that we have taken has several advantages:
-the lipid backbone is much more stable during the extrusion process and during storage than a protein anchor -the amount of glycan decorating the surface can be reproducibly adjusted by altering the amount in the extrusion 7-Day Biodefense: ENVELOP
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-the glycan and glycolipids can undergo independent QC prior to incorporation The disadvantages of this approach are that the glycan must go through the extrusion process, which can affect its structure and stability. Also, using this method, the interior-facing surface of the liposome membrane will also express surface glycans though they are not available for binding. This may impact cost of production. Developing appropriate attachment chemistry and improving the glycolipid yield and purity turned out to be a major focus of the program.
LSTc glycolipid
In a standard sythesis, roughly 10 mg of purified LSTc is conjugated to the DOPE lipid anchor using the heterobifunctional linker N-(Fmoc-13-amino-4,7,10-trioxa-tridecyl)-succinamic acid. We use a two step process where the first step is attachment of the amine-linked unsaturated phospholipid, 1,2-Dioleoyl-snGlycero-3-Phosphoethanolamine (DOPE), to an Fmoc-protected linker acid using EDC as coupling reagent. The reaction product is purified by silica gel chromatography then the Fmoc deprotected to provide the amine for attachment with the free non-reducing sugar aldehyde of LSTc or LSTa via reductive beta elimination. This is described in Figure 10 . After completion of the reaction the final product is (partially) purified using column chromatography. The partially purified product is the initially characterized by MALDI-MS spectroscopy to confirm the final glycolipid product, measured m/z value of 2033 Da (expected, 2034 Da). Standard column chromatography and HPLC are used to purify LSTa/c-DOPE, and product characterization is performed by NMR and MALDI-MS. Final glycolipid purity is typically greater than 90% and the reaction yield is 25-30%.
Heparan Sulfate glycolipid
7-Day Biodefense: ENVELOP
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Conjugation of HS oligosaccharide to DOPE was attempted using the reductive deamination reaction described above for generation of LSTc glycolipid but yielded no HS-oligosaccharide-DOPE product. This necessitated used of an alternate synthesis scheme and, after some exploration, amino-oxy derivatization was chosen as an option. The amino-oxy synthesis scheme is diagrammed in Figure 11 . Unlike reductive amination, deprotected amino-oxy lipid inker was found to be unstable and could not be readily purified without the occurrence of significant side reactions. However, when the glycan was added to deprotected lipid-linker that was not purified (refer to the last two steps in Figure 11) , the correct glycolipid product was recovered with high yield. Subsequently, the amino-oxy reaction was utilized to synthesize a pilot batch of HS-octasaccharide DOPE, which was the appropriate mass when analyzed using mass spectroscopy and had the appropriate structure when analyzed by NMR. The amino-oxy reaction was then successfully scaled up to yield 60 mg of high purity HS-octasaccharide-DOPE glycolipid. Liposome Extrusion DOPC (18:1 PC) was chosen as base lipid for liposome formulation since its long unsaturated hydrocarbon tail imbues a low gel transition temperature that causes relatively disordered membranes that remain fluid to be formed at room temperature (25˚C) or in the human body (37˚C). The lower transition temperature of DOPC also allows liposome to be manufactured without elevated temperatures. PC-based liposomes have also been used in vivo without encountering significant safety issues. As mentioned above, DOPE (18:1 PE) is used for glycolipid production since the viral glycan receptor can be conjugated via a readily-functionalized terminal amine. Also included in some liposome formulations is a small percentage of DOPE linked to the fluorescent 7-Day Biodefense: ENVELOP 14 dye NBD that acts as a marker to assist with tracking and quantification. The related lipid DOPG (18:1 PG), which has a negatively-charged headgroup, was used to charge compensate for differing LSTc-DOPE percentages (the sialic acid on LSTc is negatively charged) (Figure 12 ). Liposomes were formulated using an extrusion technique derived from Hope, M. J. et al. 1985. (Biochim. Biophys. Acta. 812:55-65 ) typically using a 100 nm to 200 nm pore size. Initial physical characterization of the bare liposomes was performed by dynamic light scattering (Malvern Instruments Zetasizer) to measure distribution of mean particle hydrodynamic size, polydispersity and zeta potential. The lipid content of each liposome batch was determined by colorimetric assay. Liposome stability was examined during shipping and storage, and results showed no significant changes to size or polydispersity upon shipping or long term storage at 4C. Electron microscopy was also employed to assess the size and distribution of liposomes. An example of this is seen in Figure 13 . Based on image analysis, these liposomes were 30 to 110 nm in diameter with an average diameter of 40.83 ± 14.80 nm. This is similar to the values obtained by DLS. It is unclear if the sample preparation or fixation procedures may have impacted the integrity of the liposomes. The concentration of active compound was expressed as either the concentration of glycan on the surface or the concentration of liposome particles. The concentration of surface glycan depends on the mol% of glycan-DOPE incorporated into the liposome and assumes 100% incorporation based on the empirically determined lipid concentration. Liposome particle concentration is calculated from the lipid concentration, the liposome diameter, and the average size of a lipid head group. Calculated liposome concentrations were verified by nanoparticle tracking using a Nanosight device.
Liposome production under GLP
Draper has implemented the synthesis of the glycolipids using good laboratory practice (GLP) in preparation for pre-IND studies. This required implementation of SOPs for processes involved in synthesis and for maintenance, calibration, and qualification of equipment involved in the production of glycolipid, and training of Draper staff on development and execution of SOPs. A GLP-compatible protocol for production of glycanbearing liposomes was also developed. The protocol utilized by UCSB for glycan-bearing liposomes was sufficient to produce batches for research and development, but the process utilizes solvents not appropriate for use in humans and is also not scalable for making larger liposome quantities. Northern Lipids, a contract research organization that specializes in GLP/GMP production of liposomes, developed a new production process that circumvents these issues. Glycolipid was solublized in 25% H 2 O/t-butanol then mixed with other lipids (DOPC and cholesterol) follows by lyophilization at -5˚C. The lipid mixture was then reconstituted in 300 mM sucrose, 10 mM histidine pH 6.5 then extruded with 5 passes through a 200 nm membrane at 400 psi. The use of t-butanol alleviates much of the solvent-related safety concerns and the production process is scalable to multiple liter batches at concentrations up to 100 mg/ml lipid. Pilot batches of liposomes produced by Northern Lipids using this process had the same physical properties as similar batches produced at UCSB and had nearly identical activity when compared in head-to-head in in vitro studies (data not shown). This demonstrated that the newly developed production process produced effective liposomes suitable for GLP/GMP scale-up and potential use in clinical trials.
Liposome aerosolization
Studies using a cascade impactor were performed to better understand the deposition of nebulized liposomes in the airway. Fluorescently-labeled liposomes lacking LSTc were produced in the manner described at a concentration of 1, 4, or 10 mg/ml, then aerosolized using an AeroNeb nebulizer connected to the cascade 7-Day Biodefense: ENVELOP 16 impactor. Transit of liposomes through the device was determined by quantification of the fluorescent signal. As indicated in Table 1 , the majority of the liposomes (51 to 64%) ended up in the fine particle fraction, which correlated to deposition in the alveoli. 18 to 23% of the liposomes were deposited in the upper airway, thought to be the most relevant site for blocking influenza infection, and 18 to 26% were in the inhalable fraction, which correlates to deposition in the nasal passages. With an increasing concentration of liposomes, a greater proportion was in larger droplets and should be deposited in the upper airway and nasal passages. This data indicates that it is possible to achieve 20 to 25% deposition of liposomes in the upper airway, which would be the desired target for prophylaxis. 
In vitro activity of LSTc-bearing liposomes Inhibition of HA binding to surface-bound glycans by LSTc-labeled liposomes
The glycan array was initially used to assess the ability of liposomes to block influenza HA from interacting with its receptor. This assay uses HA isolated from various influenza A strains and precomplexed with primary and secondary antibodies (resulting in four subunits locked together spatially) to more accurately represent the multimeric binding that occurs between influenza virions and cells. Results with precomplexed HA are reflective of natural binding as evidenced by the similar glycan binding specificity of precomplexed H1, H2, or H5 HAs to that of whole virions expressing the corresponding HA. To assess liposome efficacy, LSTa or LSTc attached to a surface was probed with pre-complexed HA from the influenza strain Alb58 or Viet04. Alb58 is of the H2 subtype and human-adapted so that it shows predominant binding to 2→6 linked SA like that of LSTc, while Viet04 is of the H5 subtype and preferentially binds to 2→3 linked SA like that of LSTa. In the absence of glycan-bearing liposomes, pre-complexed Alb58 HA bound well to LSTc but not to LSTa and precomplexed Viet04 HA demonstrated a preference for binding to LSTa over LSTc (Figure 14) . Alb58 HA binding to LSTc was nearly completely inhibited by 27.5 fmol LSTc-bearing liposomes, while binding of Viet04 to LSTa or to LSTc was unaffected. This indicated that LSTc-labeled liposome can block binding of HA from a humanadapted strain to an 2→6 linked SA but not HA from an avian-adapted strain to an 2→3 linked SA. Conversely, liposomes bearing 15 mol% LSTa were not able to inhibit the binding of Alb58 to LSTc and, surprisingly, were also only partially effective in competing with the interaction of Viet04 with LSTa on the array surface. This demonstrated that the LSTa-labeled liposomes had a lower affinity for influenza HA specific for 2→3 linked SA than LSTc liposomes do for HA specific for 2→6 linked SA. This was confirmed in subsequent assays examining the ability of glycan-bearing liposomes to block MDCK infectivity.
Figure14: Glycan array analysis of the effect of glycan-bearing liposomes on the binding of pre-complexed Alb58 or Viet04 HA to surface-bound LSTc (red) or LSTa (blue). Influenza HA was mixed with buffer only or the LSTc-labeled liposomes (15 mol% LSTc -left) or the LSTa-labeled liposomes (15 mol% LSTa -right) at the amount indicated, then bound to the glycan array.
Hemagglutination inhibition (HAI) assays
HAI was used as another screen of the anti-HA activity of different liposome batches since it can rapidly assess binding efficacy against different influenza A strains. Influenza A agglutinates RBCs to form a sheet and inhibition of this hemagglutination can be readily measured. Assessment of the HAI activity of LSTc-and LSTacontaining liposomes against range of influenza A strains showed that LSTc-containing liposomes inhibited the strains tested with a K i HAI in the nM range ( Table 2) . Soluble LSTc showed no inhibitory capability at >740 µM glycan, the maximum concentration tested, which showed that attachment of LSTc to the liposome surface resulted in more than a 1000-fold increase in binding activity. LSTa-containing liposomes were less effective at inhibiting hemagglutination than LSTc-containing liposomes and had no measureable inhibitory effect on the hemagglutination by human-adapted influenza A/Beijing. Additional data is summarized in our initial publication Hendricks et. al. (2013) . replication of a variety of influenza virus subtypes and strains. Glycan-bearing liposomes generally had no significant acute effect on the viability of MDCK cells, even at high concentration, when assayed using lactate dehydrogenase (LDH) release into the culture medium or other toxicity assays.
Over twenty different batches of LSTc-bearing liposomes, varying in formulations and/or production method, were produced and tested in MDCK cell infection assays. This series of experiments is summarized below:
-Inhibitory activity increased as the mol% of LSTc-glycolipid in the liposome formulation, and thus the amount of LSTc on the liposome surface, was increased from 0 to 7.5 mol% LSTc (Hendricks et al, 2013) . Less total LSTc was required with LSTc-bearing liposomes with 7.5 mol% glycan compared to 5 or 1 mol% glycan, which indicated that liposomes with 7.5 mol% glycan were more effective. This was likely due to the improved multivalent interaction achieved by adding more LSTc to the liposome surface. -LSTc-liposome inhibitory efficacy did not increase significantly when the LSTc concentration was increased beyond 7.5 mol%. Liposomes preparations with 15 or 30 mol% LSTc had roughly the same activity (Figure 15 ). This suggests a limit to the number of glycans that can be appropriately displayed from the glycan surface and/or interact with the influenza virion. -When different extrusion membranes were utilized it became apparent that larger liposomes (100 to 130 nm diameter) have increased activity over their smaller (60 to 80 nm diameter) counterparts. -The inclusion of 30% cholesterol improved the ability of liposomes to inhibit influenza infection, particularly with PR/8. -Additional negative surface charge slightly increased liposome in a strain-specific manner.
-The inclusion of 10 mol% PEG-1000 reduced liposome efficacy in the formulations tested. Based on these results, a formulation consisting of 7.5 mol% LSTc-DOPE, 30% cholesterol, 62.5% DOPC with extrusion through a 200 nm membrane to produce liposomes in the 100 to 150 nm range was the process used to produce LSTc-labeled liposomes.
LSTc-labeled liposomes produced by this method were tested for their ability to prevent the cytopathic effects (CPE) of influenza virus on MDCK cells (Figure 17) . LSTc-bearing liposomes and influenza virus were left in contact with cells for 48 hours and the amount of cytotoxicity was then assessed. The concentration of LSTclabeled liposomes that achieved 50% inhibition of CPE (IC 50 ) depended on the amount of PR/8 viral challenge, with IC 50 s of 10 nM with 0.1 MOI, 1.5 nM with 0.01 MOI, and 0.02 nM with 0.001 MOI. In a control experiment, liposomes lacking LSTc had no effect on CPE. This demonstrated that LSTc-labeled liposomes had long lasting ability to block influenza virus and protect cells from infection.
Using this same assay, LSTc-labeled liposomes were demonstrated to inhibit cell death caused by a range of H1N1 or H3N2 influenza strains, including human-adapted and pandemic (California/09 and San Diego/09) strains ( Table 3) . The ED50 ranged from 160 nm to roughly 1 µM LSTc, or 16 to 110 nM liposomes, depending on the strain. This confirmed that LSTc-liposomes had broad specificity in blocking influenza infection. The CC 50 of LSTc-bearing liposomes for MDCK or primary airway epithelial cells, determined using alamar blue staining, was >75 µM LSTc. This yields a selectivity index (CC50/ED50) of ≥ 75 for LSTc-bearing liposomes, which is an initial indication that treatment is well-tolerated. Additional data demonstrating the ability of LSTclabeled liposomes to reduce viral propagation and yield is published in Hendricks et al. (2013) .
LSTc-bearing liposomes were also shown to block influenza infection of primary human bronchial epithelial (normal human bronchial epithelium or NHBE) cells, which are more representative of the type of airway cells encountered during infection. These commercially-available NHBE cells differentiate into representative airway epithelia when incubated in an air-liquid interface, i.e. with the basolateral surface bathed in medium and the apical surface exposed to air, and display different sialyated receptors than MDCK cells. PR/8 was able to effectively infect and propagate within these cells and, as monitored by the FFA assay, and LSTc-labeled liposomes were able to effectively block PR/8 infection and propagation in a concentration-dependent fashion (Figure 18) . 3 nM LSTc-labeled liposomes reduced the fluorescent signal produced by influenza nucleoprotein by 70% relative to control liposomes lacking LSTc. The concentration of LSTc-bearing liposomes was roughly 100-fold greater than that needed to block influenza propagation in MDCK cells.
Figure 18. Efficacy of LSTc-bearing liposomes in inhibiting PR/8 infection of primary human bronchial cells (NHBE).
Liposomes with 7.5 mol% LSTc (red) or those lacking LSTc (gray) were added to NHBE cell monolayers immediately prior to the addition of PR/8. A PR/8 infection lacking liposome treatment (blue) served as a control.
In vivo activity of current LSTc-bearing liposome formulations
We performed a number of independent studies that indicated LSTc-labeled liposomes, when mixed with virus prior to instillation, inhibit influenza PR/8 in the mouse model of infection. A summary of three replicate experiments was published in Hendricks et al. (2013) and is presented in Figure 19 . Mice that received LSTcbearing liposomes had a 33% increase of mean survival time post-infection compared to mice that received liposomes lacking LSTc. LSTc-bearing liposomes at the same dose that demonstrated efficacy when pre-mixed with virus prior to infection were not effective when given one hour prior to influenza infection. Since in vitro data suggests that liposomes are stable for at least 4 hours in up to 50% serum (data not shown), the lack of efficacy of prophylactic treatment in the mouse model is likely due to liposomes being transported by mucus and/or diluted after installation so that they were not at sufficient concentration to inhibit the newly-instilled virus. LSTc-bearing liposomes also did not demonstrate significant efficacy in limiting infection from a lethal dose of Philippines X-79 (H3N2), despite having significant in vitro activity against this strain (Figure 20) . Due to inter-strain differences, a higher dose of Philippines X-79 (at least 7,000 PFU vs. 1,000 PFU of PR/8) is needed to achieve an LD 95 via orotracheal instillation in the mouse model. Since the likely mechanism of action of the liposomes is direct competitive inhibition, we would anticipate a 7-fold higher dose of liposomes is required to inhibit infection by the Philippines X-79 strain. This can be achieved by either increasing the liposomes dose or by giving daily or twice daily doses.
Pharmacokinetics of LSTc-bearing liposomes
The in vivo fate of LSTc-bearing liposomes was assessed in pharmacokinetic studies where radiolabeled liposomes were instilled into the respiratory tract of mice. Initial studies were performed with liposomes lacking LSTc (62.5 mol% DOPC, 30 mol% cholesterol, and 7.5 mol% DOPG) and labeled with 3 H-cholesterol hexadecyl ether (0.05 µCi/mouse), which incorporates into the liposomal membrane, and 14 C-sucrose (0.05 µCi/mouse), which was encapsulated. Using liposome preparations of 10 or 100 mg/ml lipid, equivalent to 25 or 250 mg/kg, a significant proportion of the 3 H-cholesterol hexadecyl ether remained in the lungs of mice for the 72 hour duration of the experiment (Figure 21 ). This indicated that lipids present in the delivered liposomes remain in the airway of mice for at least several days. Conversely, over 90% of the 14 C-sucrose was eliminated by 24 hours, which suggested that the liposome contents are retained in the mouse airway for a much shorter period. Possible explanations for the difference between the fate of the labeled substances could be that the liposomes were disrupted or that they become "leaky" to small molecules such as sucrose when exposed to protein and lipid surfactants in the airway. The pharmacokinetic profile was not dependent on the liposome concentration. The in vivo fate of liposomes labeled with 7.5 mol% LSTc was determined in a similar manner but without the encapsulatation of 14 C-sucrose since results using that isotope were largely uninformative. In the lungs of mice sacrificed immediately after instillation of the 3 H-labeled LSTc-bearing liposomes, only 37% of the radioactivity was recovered, which indicated significant losses to the nasal passages, esophagus, or elsewhere (Figure 22) . Of the radiolabel that entered the lungs, its disappearance is biphasic with 30% of the recoverable cholesterol remaining associated with the lungs for 14 days or more. Our presumption is that the first phase represents the fate of intact liposomes and that these have a t 1/2 of roughly 1.5 d. The second phase represents cholesterol that is dissociated from liposomes and incorporated into lung tissue so that it remains in the lung for 2 weeks or more. However, the integrity of the liposomes cannot be determined and future studies will be designed to evaluate the PK of intact liposomes and their correlation to anti-viral activity. 
LSTa-labeled liposomes
Liposomes containing 30mol% LSTa were over 10-fold less effective than similar LSTc-labeled liposomes against the mouse-adapted PR/8 (H1N1) strain and at least 4-fold less effective than LSTc-labeled liposomes against Philippines (H3N2) strain ( Table 1) . Additional experiments demonstrated that liposomes with 7.5 mol% or 15 mol% LSTa inhibited the H1N1 and H3N2 strains but at a 100-fold higher concentration than LSTclabeled liposome for PR/8 (11.7 nM vs. 50 pM) and at over a 30-fold greater concentration than that needed to block Philippines X79 (15.5 nM vs. 390 pM). Clearly, the LSTa-labeled liposomes were less effective than LSTc-labeled liposomes in interacting with mouse-adapted strains and blocking infection in vitro. This was possibly due to the HA binding specificity of the particular mouse-adapted strains used or due to differences in the presentation of LSTa and LSTc on the liposome surface.
We examined if the two liposome types could act synergistically to block influenza infectivity. Different amounts of LSTc-labeled liposomes (15 mol% LSTc) were combined with various amounts of LSTa-labeled liposomes (15.5 mol% LSTa), then were mixed with either PR/8 or Philippines and assayed for their ability to block MDCK infectivity. The efficacy of LSTa-labeled liposomes or LSTc-labeled liposomes alone versus PR/8 was similar to that seen in other experiments. There appeared to be a slight improvement in the activity of LSTc-bearing liposomes in the presence of LSTa-labeled liposomes that did not elicit an effect alone (93 pM or 310 pM - Figure 23 ), but no synergistic effect was seen when the experiment was repeated with the Philippines (H3N2) strain. This suggested that any possible synergistic effect of the two liposome types is strain or subtype specific, and a mixture of LSTa-and LSTc-bearing liposomes provided no advantage over LSTc-7-Day Biodefense: ENVELOP 25 labeled liposomes alone. Also, since LSTc-bearing liposomes alone were highly effective in blocking the mouseadapted H1N1 and H3N2 influenza strains and LSTc is most relevant glycan for blocking infection by humanadapted influenza A strains (due to their reliance on 2→6 sialylated, umbrella-like glycan receptors), a programmatic decision was made to focus solely on optimization, testing, and development of liposomes bearing LSTc with no further research on LSTa-bearing liposomes. 
Mechanism of action of LSTc-bearing liposomes
To support our hypothesis that the mechanism of action of the LSTc-labeled liposomes was through binding to the virus, transmission electron microscopy was used to assess the interaction of LSTc-bearing liposomes and influenza PR/8. Roughly 10 9 LSTc-labeled liposomes diluted in PBS were mixed with 10 5 PFU of PR/8 then added to carbon-coated grids for imaging. LSTc-bearing liposomes bind to and accumulate around the virus particles, while control liposomes lacking LSTc do so to a significantly lesser extent (Figure 24 ). This indicated that LSTc on the liposome surface initiates interaction with the virus. In these images, the liposomes appear fairly heterogeneous in size, which may be due to a result of the preparation procedure. To further study anti-influenza liposome mechanism of action, we compared the efficacy of LSTc-labeled liposomes added prior to, during, and after infection of MDCK cells with PR/8 (H1N1). More efficacy was achieved when the LSTc-labeled liposomes and virus were pre-mixed for 30 minutes prior to infection, which inhibited viral yield roughly 80% (Figure 25) . Adding LSTc-labeled liposomes to the MDCK cells immediately prior to influenza virus also caused a significant reduction in infection of approximately 70%, not statistically different than pre-mixing liposomes and virus. Prophylactic addition of the LSTc-labeled liposomes to the cells 1 hour prior to viral infection reduced their ability to inhibit infection, with viral yield blocked 50%. When LSTclabeled liposomes were added 1 hour after infection, they had no ability to reduce viral propagation. These results are consistent with LSTc-bearing liposomes interfering with the binding of influenza HA to receptors on the MDCK cell surface. The liposomes perform best when given an opportunity to bind virions prior to infection but are ineffective once influenza has an opportunity to interact with cells. To further study the efficacy of LSTc-labeled liposomes added prophylactically, LSTc-labeled liposomes were added to MDCK cells 2 to 6 hours prior to infection with PR/8. Compared to liposomes lacking LSTc, LSTcbearing liposomes caused a 41 to 66% reduction in infection when added 2 to 6 hours prior to virus ( Figure  26) . When LSTc-labeled liposomes were pre-mixed with PR/8, infection was reduced 86% in this assay. So, while prophylactic addition of liposomes was not as effective as pre-mixing, liposomes were still effective when added up to 6 hours prior to virus infection. This indicated that the liposomes are stable in tissue culture for many hours and demonstrated stability under physiologic conditions. These results confirmed what was seen in PK studies. Binding comparisons of liposome formulations using surface plasmon resonance Surface plasmon resonance (SPR) imaging detects the presence of an analyte on a chemically modified gold surface by the change in local index of refraction that occurs upon adsorption. The SPR signal is a measure of mass concentration at the sensor chip surface, allowing analyte and ligand association and dissociation to be observed. From these observations, rate constants as well as equilibrium constants can be calculated. Using SPR, we assessed the affinity of LSTc-labeled liposomes for HA from human-adapted influenza A/New Caledonia/20/99 (H1N1). The HA from this strain, similar to that of other human-adapted strains, preferentially binds to glycans like LSTc that terminate in 2→6 linked SA and adopt an umbrella conformation. 7.5 mol% LSTc-bearing liposomes were shown to interact with HA purified from IFA H3N2 with a K d of 580 pM, which represents high affinity binding similar to effective anti-influenza antibodies (Figure 27 ). Efficacy of combinations of LSTc-labeled liposomes and influenza neuraminidase inhibitors Influenza neuraminidase (NA) hydrolyzes the terminal sialic acid residues on newly formed virions and host cell receptors to help virus release from infected cells and spread within the respiratory tract. LSTc, like all influenza receptor glycans, contains a terminal sialic acid with the potential to be hydrolyzed by influenza NA, which would result in LSTc-labeled liposomes being rendered less effective. To see if inhibition of influenza NA enhanced LSTc-labeled liposome efficacy, liposomes were combined with two specific NA inhibitors, oseltamivir and zanamivir, each of which is FDA-approved for influenza therapy in humans. The NA inhibitors enhanced LSTc-labeled liposome anti-viral activity. Data for zanamivir is shown (Figure 29) , and experiments with oseltamivir produced similar results. A single dose of 1 or 10 µM zanamivir mixed with influenza PR/8 and plain liposomes lacking LSTc did not have a significant effect on viral yield. However, this same zanamivir dose was able to enhance the inhibitory activity of LSTc-labeled liposomes when co-incubated with virus and liposomes. This indicated that inclusion of a NA inhibitor during virus-liposome interaction increased liposome efficacy. Therefore, sialic acid on the LSTc decorating the liposome surface appears to be hydrolyzed by influenza NA and this can diminish the inhibitory ability of liposomes. This hypothesis was then tested in a mouse model using PR/8. Because zanamivir has a short in vivo half-life, a single dose of zanamivir at the appropriate concentration should inhibit influenza NA in the short term but not significantly inhibit progression of influenza infection in the mouse. Pilot studies identified 0.01 mg/kg zanamivir the appropriate dose for a 1,000 PFU infectious dose of PR/8 (data not shown). To test the if NA inhibitor present during pre-mixing increased in vivo efficacy of LSTc-labeled liposomes, zanamivir was added to liposome/virus mixtures during their incubation period. As Figure 30 illustrates, LSTc-labeled liposomes, both untreated and treated with zanamivir, had a significant effect on reducing mortality associated with infection by influenza PR/8. None of the mice treated with PR/8 only or PR/8 exposed to liposomes lacking LSTc survived after day 11 post-infection. However, mice treated with the LSTc-bearing liposomes D survived longer (until day 14) and had significantly less infection-associated mortality, with 3/8 mice surviving the ** ** ** * ** * 7-Day Biodefense: ENVELOP 30 study, than mice receiving virus only or virus plus matching liposomes lacking LSTc (p = 0.005). 25 μM zanamivir alone slightly inhibited PR/8 infection, as 2/6 mice treated with a single dose of zanamivir survived (p = 0.007 vs. no treatment) and 1/8 mice receiving zanamivir plus liposomes lacking LSTc survived (p = 0.103 vs. liposomes lacking LSTc only). There was no significant difference in the survival of mice receiving LSTc-labeled liposomes with or without zanamivir (p = 0.812). So while this study indicated that LSTc-labeled liposomes themselves are effective in increasing the length of survival and reducing mortality in mice infected with influenza virus, the effect of NA inhibitors on liposome efficacy in this in vivo study was not significant. Additional studies are needed to better understand the degree by which viral neuraminidase affects glycan-labeled liposomes in vivo.
In addition to combining exogenous NA inhibitors with LSTc-labeled liposomes, we explored loading LSTclabeled liposomes with the zanamivir in order to increase efficacy. Loading was accomplished by performing liposome extrusion in the presence of zanamivir solution. Both LSTc-labeled and unlabeled liposomes loaded with 200 µM zanamivir were generated and their ability to block PR/8 infection of MDCK cells was measured (Figure 31) . Zanamivir encapsulated in the liposome greatly increased the efficacy of both unlabeled and LSTclabeled liposomes in blocking influenza infection, and the zanamivir-loaded LSTc-labeled liposomes inhibited infection nearly completely. This again demonstrated the synergy of LSTc-labeled liposomes with current NA inhibitors. It also highlighted the potential of using the liposomal platform to specifically deliver small molecule therapeutics to virus. If SA-glycan bearing liposomes are indeed adversely affected by influenza NA, it is possible to redesign the sialic acid linkage on LSTc (or LSTa, if needed) so that it is resistant to NA hydrolysis. This would entail use of a glycan with a different core that would be isolated then modified chemoenzymatically for NA-resistance. Purification of the glycan, modification, incorporation into glycolipid, extrusion into liposomes, and testing NA resistance and binding is a significant undertaking that will be reserved for later project stages if deemed necessary. A less attractive approach is to develop a dosing strategy where an NA inhibitor is co-administered with LSTc-labeled liposomes; this may be onerous if used in therapy.
HSocta-bearing liposomes
This HS-octasaccharide DOPE was the used in a pilot study to produce HS-octsaccharide bearing liposomes. Using the standard formulation used for LSTc-bearing liposomes (7.5 mol% glycolipid, 30% cholesterol, and 62.5% DOPC), extrusion of liposomes containing 7.5 mol% HS-octasaccharide DOPE through a 200 nm membrane produced 140 nm diameter liposomes that had the same general physical characteristics as similar batches of LSTc-bearing liposomes. These liposomes were found to be over 1000x more effective in inhibiting RSV infection of Vero cells than purified HS-octasaccharide in solution (unpublished). A 50% reduction in RSV infectivity was achieved with roughly 500 µM HS-octasaccharide in solution compared to 100 nM HSoctasaccharide on the surface of liposomes. This showed that display of the HS-octasaccharide on the surface of liposomes recreated the multivalent binding to the RSV F and G proteins and increased affinity to the RSV virion. We will next test different amounts of HS-octasaccharide on the liposome surface to see if we can improve in vitro activity versus RSV. We will then test efficacy in a mouse model of RSV infection, with HSoctasaccharide-bearing liposomes and RSV instilled via the intranasal route, and viral titers, cytokines, and histopathology used as endpoints. Demonstration of the efficacy of anti-RSV liposomes is particularly promising since it is the HS-octasaccharide should be able to interact with and inhibit other virus, or it can be combined with LSTc or similar glycans on the liposome surface to increase the spectrum of activity. Another promising future direction is exploiting the immunomodulatory properties of heparin-derived glycans to combine their effect with anti-viral activity.
